Copenhagen, Denmark - 4 May 2011 - Topotarget A/S (NASDAQ OMX: TOPO.CO)
announces that a teleconference will be held on 10 May 2011 at 2:00 pm local
time. CEO Francois Martelet and CFO Anders Vadsholt will present the Q1 2011
interim report and answer questions. The teleconference will be conducted in
English. A presentation will be available on Topotarget's website,
www.topotarget.com, before the start of the conference call.

To participate in the conference call please dial:

- From Denmark: 70 26 50 40

- Outside Denmark: +45 70 26 50 40 or 0800 634 5205 (UK) or 1866 629
2704 (US) or 0200 125 785 (SE)

A replay of the conference call will be available approximately two hours after
the conference call and until 10 August 2011 at: +353 1 436 4267 or +44 207 769
6425, pass code: 4824 868#. A replay will also be available on Topotarget's
homepage www.topotarget.com.


Topotarget A/S


For further information, please contact:


Annette Lykke, IR Direct: +45 39 17 83 44; Mobile: +45
23 28 98 14


Background information


About Topotarget

Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti-neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of other chemotherapeutic agents, and is currently in a pivotal trial
within PTCL (peripheral T-cell lymphoma) and Phase II in cancer of unknown
primary site (CUP). Topotarget's cancer drug targets are HDAC, NAD+, and
topoisomerase II. Totect® is a product on the market developed from
Topotarget's drug discovery technology. Totect® is marketed by the company's
own sales specialists in the US. The European rights to Savene® were divested
in March 2010 as a consequence of the focus to develop and commercialize
belinostat. For more information, please refer to www.topotarget.com.


Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Investor News No 02-11 Time and date for telephone conference re publishing of Q1 2011.pdf